摘要
目的:研究紫杉醇联合伊立替康(CPT-11)治疗中期胃癌的近期临床效果及不良反应。方法:将105例中期胃癌患者按照入院时间的先后顺序分为对照组(52例)与观察组(53例),观察组采用紫杉醇联合CPT-11治疗、对照组采用紫杉醇治疗,对比两种治疗方法的效果。结果:观察组患者的治疗有效率为75.5%,高于对照组的63.5%(P<0.05);观察组患者不良反应发生率为11.3%,低于对照组的28.8%(P<0.05)。结论:在中期胃癌的治疗中联合使用紫杉醇与CPT-11,能够提高治疗的整体有效率并降低治疗过程中的不良反应,提高治疗的安全性。
Objective:To study the short-term clinical efficacy and adverse reactions of paclitaxel combined with CPT-11 in the treatment ofintermediate gastric cancer. Methods:105 patients with intermediate gastric cancer were divided into the control group (n=52) and the observation group (n=53) according to the chronological order of hospitalization. The observation group was treated with paclitaxel combined with CPT-11 while the control group was treated with paclitaxel, with the clinical effects compared. Results:The effective rate of the observation group was75. 5 %, higher than that of the control group (63.5 %)( P〈0.05). The incidence rate of adverse reactions in the observation group was 11.3 %, lower than that of the control group (28.8 %)(P〈0.05). Conclusion: Paclitaxel combined with CPT-11 in the treatment of intermediate gastric cancer can improve the overall efficiency and reduce the adverse reactions during the treatment, and improve the safety of the treatment.
作者
陈世超
CHEN Shichao(The Second People' s Hospital of Luohe,Henan,Luohe 462000,China)
出处
《包头医学院学报》
CAS
2018年第6期64-65,共2页
Journal of Baotou Medical College
关键词
中期胃癌
紫杉醇
伊立替康
Intermediate gastric cancer
Paclitaxel
CPT-11